公开(公告)号：US20240408098A1

公开(公告)日：2024-12-12

申请号：US18694848

申请日：2022-10-04

Applicant: MIRATI THERAPEUTICS, INC.

Inventor： Jill Hallin ,  James Gail Christensen ,  Vickie Bowcut ,  Peter Olson

IPC: A61K31/519 ,  A61K31/4439 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12D cancers: in particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a PI3Ka inhibitor and a KRas G12D inhibitor, pharmaceutical compositions comprising a such compositions, kits comprising such compositions and methods of use thereof.

公开(公告)号：US20220331323A1

公开(公告)日：2022-10-20

申请号：US17713455

申请日：2022-04-05

Applicant: Mirati Therapeutics, Inc.

Inventor： Lars Daniel Engstrom ,  Peter Olson ,  James Gail Christensen

IPC: A61K31/519 ,  A61P35/00 ,  A61K31/506

Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with CDK4/6 inhibitors.

公开(公告)号：US20240423987A1

公开(公告)日：2024-12-26

申请号：US18825566

申请日：2024-09-05

Applicant: Mirati Therapeutics, Inc.

Inventor： Lars Daniel Engstrom ,  Peter Olson ,  James Gail Christensen

IPC: A61K31/519 ,  A61K31/416 ,  A61K31/502 ,  A61K31/517 ,  A61P35/00

Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with KRASG12C inhibitors.

公开(公告)号：US20240423984A1

公开(公告)日：2024-12-26

申请号：US18694921

申请日：2022-10-04

Applicant: MIRATI THERAPEUTICS, INC.

Inventor： Jill Hallin ,  James Gail Christensen ,  Vickie Bowcut ,  Peter Olson

IPC: A61K31/519 ,  A61K31/497 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12D cancers, In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a. therapeutically effective amount of a combination of a SHP-2 inhibitor and a KRAS G12D inhibitor of Formula (I), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use thereof.

公开(公告)号：US11890285B2

公开(公告)日：2024-02-06

申请号：US17029654

申请日：2020-09-23

Applicant: Mirati Therapeutics, Inc.

Inventor： David Briere ,  James Gail Christensen ,  Peter Olson

IPC: A61K31/519 ,  A61P35/04 ,  C07K16/28

CPC classification number: A61K31/519 ,  A61P35/04 ,  C07K16/2818 ,  C07K16/2827

Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a an agent that blocks Programmed Death-1 receptor (PD-1) and Programmed Death Ligand-1 (PD-L1) signaling and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, kits comprising the compositions and methods of use therefor.

公开(公告)号：US20220096482A1

公开(公告)日：2022-03-31

申请号：US17275177

申请日：2019-09-09

Applicant: Mirati Therapeutics, Inc.

Inventor： James Gail Christensen ,  Ruth Wei Aranda ,  Lars Daniel Engstrom ,  Jill Hallin ,  Peter Olson

IPC: A61K31/519 ,  A61K31/506 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a CDK 4/6 inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

公开(公告)号：US20250108055A1

公开(公告)日：2025-04-03

申请号：US18906104

申请日：2024-10-03

Applicant: Mirati Therapeutics, Inc.

Inventor： Ruth Wei Aranda ,  James Gail Christensen ,  Lars Daniel Engstrom ,  Jill Hallin ,  Peter Olson

IPC: A61K31/519 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Raf family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

公开(公告)号：US12171765B2

公开(公告)日：2024-12-24

申请号：US17713455

申请日：2022-04-05

Applicant: Mirati Therapeutics, Inc.

Inventor： Lars Daniel Engstrom ,  Peter Olson ,  James Gail Christensen

IPC: A61K31/519 ,  A61K31/506 ,  A61P35/00

Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with CDK4/6 inhibitors.

公开(公告)号：US20240408099A1

公开(公告)日：2024-12-12

申请号：US18694867

申请日：2022-10-04

Applicant: MIRATI THERAPEUTICS, INC.

Inventor： Jill Hallin ,  James Gail Christensen ,  Vickie Bowcut ,  Peter Olson

IPC: A61K31/519 ,  A61K31/517 ,  A61K39/395 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12D cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a pan ErbB family inhibitor and a KRAS G12D inhibitor of Formula (I), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

公开(公告)号：US12128048B2

公开(公告)日：2024-10-29

申请号：US17713472

申请日：2022-04-05

Applicant: Mirati Therapeutics, Inc.

Inventor： Lars Daniel Engstrom ,  Peter Olson ,  James Gail Christensen

IPC: A61K31/519 ,  A61K31/416 ,  A61K31/502 ,  A61K31/517 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K31/416 ,  A61K31/502 ,  A61K31/517 ,  A61P35/00 ,  A61K31/519 ,  A61K2300/00 ,  A61K31/517 ,  A61K2300/00 ,  A61K31/502 ,  A61K2300/00

Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with KRASG12C inhibitors.